Table I.
Patient baseline characteristics.
| Characteristics | PF (arm A; n=29) | PP (arm B; n=31) | P-value |
|---|---|---|---|
| Age (years) | 0.722 | ||
| Median (range) | 62 (42–75) | 62 (40–75) | |
| Gender | 0.389 | ||
| Male:female | 24:5 | 28:3 | |
| Karnofsky performance status | 0.898 | ||
| Median (range) | 80 (70–100) | 80 (70–100) | |
| Location | 0.787 | ||
| Cervical:upper:middle:lower | 4:11:12:2 | 3:12:12:4 | |
| Stage | 0.266 | ||
| IIa:IIb:III:IVa | 4:0:16:9 | 6:3:12:10 | |
| Tumor length (cm) | 0.576 | ||
| Median (range) | 6.5 (2.0–11.5) | 5.0 (3.5–10.0) |
PF, cisplatin and 5-fluorouracil; PP, cisplatin and pemetrexed.